ArticleThe Lancet. Oncology2016
Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study.
Article in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis.International journal of public health · 2019Pooled it
- Educational inequalities in cervical cancer mortality in the Baltic countries and Finland in the context of organized screening: A register-based study 2000-2015.International journal of cancer · 2026Article
- The role of the health belief model and HPV self-testing in cervical cancer screening participation in the Czech Republic.BMC women's health · 2026Article
- Temporal trends in cervical cancer incidence and mortality in economically emerging countries, 1992-2021: an age-period-cohort analysis.BMJ global health · 2026Article
- European Code Against Cancer, 5th edition - organised cancer screening programmes.Molecular oncology · 2026Review
- Trends and urban-rural disparities in cervical cancer epidemiology in China, 2005-2018.Scientific reports · 2025Article
- Current Status of the National Cancer Screening Program in Korea: History, Achievements, and Future Directions.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025Article
- Trends and projections in cervical cancer incidence in northern Tunisia (1994-2040).BMC cancer · 2025Article
- Analysis of the global burden of cervical cancer in young women aged 15-44 years old.European journal of public health · 2024Article
- Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- IRTKS contributes to the malignant progression of cervical cancer cells.Medical oncology (Northwood, London, England) · 2024Article
- Predictive modeling and web-based tool for cervical cancer risk assessment: A comparative study of machine learning models.MethodsX · 2024Article
- Breast and cervical cancer screening practices in nine countries of Eastern Europe and Central Asia: A population-based survey.Journal of cancer policy · 2023Article
- Cervical cancer screening outcomes in public health facilities in three states in Nigeria.BMC public health · 2023Article
- Association Between Cervical Cancer Screening Guidelines and Preterm Delivery Among Females Aged 18 to 24 Years.JAMA health forum · 2023Article
- LncRNA HOTAIR enhances RCC2 to accelerate cervical cancer progression by sponging miR-331-3p.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Non-adherence to cervical cancer screening recommendations among women in Eswatini: a cross-sectional study.BMC public health · 2023Article
- Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study.The Lancet regional health. Europe · 2023Article
- Prevalence, incidence, and mortality rates of breast cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2019.Frontiers in public health · 2023Article
- Inequalities in reported use of cervical screening in Estonia: results from cross-sectional studies in 2004-2020.BMC women's health · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundCervical cancer incidence remains high in several Baltic, central, and eastern European (BCEE) countries, mainly as a result of a historical absence of effective screening programmes. As a catalyst for action, we aimed to estimate the number of women who could be spared from cervical cancer across six countries in the region during the next 25 years, if effective screening interventions were introduced.
methodsIn this population-based study, we applied age-period-cohort models with spline functions within a Bayesian framework to incidence data from six BCEE countries (Estonia, Latvia, Lithuania, Belarus, Bulgaria, and Russia) to develop projections of the future number of new cases of cervical cancer from 2017 to 2040 based on two future scenarios: continued absence of screening (scenario A) versus the introduction of effective screening from 2017 onwards (scenario B). The timespan of available data varied from 16 years in Bulgaria to 40 years in Estonia. Projected rates up to 2040 were obtained in scenario A by extrapolating cohort-specific trends, a marker of changing risk of human papillomavirus (HPV) infection, assuming a continued absence of effective screening in future years. Scenario B added the effect of gradual introduction of screening in each country, under the assumption period effects would be equivalent to the decreasing trend by calendar year seen in Denmark (our comparator country) since the progressive regional introduction of screening from the late 1960s.
findingsAccording to scenario A, projected incidence rates will continue to increase substantially in many BCEE countries. Very high age-standardised rates of cervical cancer are predicted in Lithuania, Latvia, Belarus, and Estonia (up to 88 cases per 100 000). According to scenario B, the beneficial effects of effective screening will increase progressively over time, leading to a 50-60% reduction of the projected incidence rates by around 2040, resulting in the prevention of cervical cancer in 1500 women in Estonia and more than 150 000 women in Russia. The immediate launch of effective screening programmes could prevent almost 180 000 new cervical cancer diagnoses in a 25-year period in the six BCEE countries studied.
interpretationBased on our findings, there is a clear need to begin cervical screening in these six countries as soon as possible to reduce the high and increasing incidence of cervical cancer over the next decades.
fundingNone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.